New MRI technique to assess brain tumors after treatment
Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases
This study is testing a new MRI method to see if it can tell the difference between real tumor growth and changes caused by treatment in people with brain tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 119 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05559853 on ClinicalTrials.gov |
What this trial studies
This study aims to develop and test a novel magnetic resonance imaging (MRI) technique designed to differentiate between tumor growth due to cancer progression and growth resulting from treatment effects in patients with brain tumors. Participants include both healthy volunteers and patients with untreated brain metastases who are scheduled for stereotactic radiosurgery (SRS). The study will utilize a specific MRI intervention known as CEST-MRF to gather data on brain tumor changes post-treatment.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with at least one untreated brain metastasis greater than 1 cm.
Not a fit: Patients without a known cancer diagnosis or those with no untreated brain metastases will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and treatment strategies for patients with brain metastases.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in utilizing advanced imaging techniques for tumor assessment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Healthy volunteers \[for Study Aim 1 (SA1) and Study Aim 2 (SA2)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * No known cancer diagnosis Patients \[for Study Aim 1 (SA1)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) Patients \[for Study Aim 3 (SA3)\] will be entered into the study if they meet the following criteria: * Age ≥ 18 years * Able to understand and give informed consent * At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist) * Planned SRS treatment Exclusion Criteria: Healthy volunteers (SA1 \& SA2) and patients (SA1 \& SA3) exclusion criteria: * Pregnant or breastfeeding women * Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest * Age \< 18 years
Where this trial is running
New York, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Ouri Cohen, PhD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Ouri Cohen, PhD
- Email: coheno1@mskcc.org
- Phone: 646-608-8259
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.